Logo
Login

Company Executives

$ Management Team

Mr. Rohan Palekar

Chief Executive Officer

Director

Age 59
Compensation $7.619M USD
Sex Male

Mr. Ryan Martins

Chief Financial Officer

Age 48
Compensation $3.416M USD
Sex Male

Mr. Quoc Le-Nguyen

Chief Technical Operations Officer

Age 57
Compensation $3.665M USD
Sex Male

Mr. Francis Sarena

Chief Operating Officer

Age 54
Compensation $2.692M USD
Sex Male

Dr. Hank Mansbach

Chief Medical Officer

Age 60
Compensation $3.689M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 15, 2025
Directors
9
serving now
Independent
8 of 9
stated in the proxy
Average tenure
4.4 years
from year joined
CEO also chairs the board
No
Steven M. Altschuler
Director Age On board Independent Committees Other public boards 2024 pay Source
Rohan Palekar
CEO
 59 2018
7 years
 Not independent None stated Neurogene Inc. Paid as CEO
Steven M. Altschuler
Board chair
 71 2020
5 years
 Independent None stated WW International, Inc. $419,967
Edward Morrow Atkinson III
59 2022
3 years
 Independent None stated None stated $388,717
Martin Babler
60 2024
1 year
 Independent None stated Prelude Therapeutics Incorporated $489,245
Derek DiRocco
44 2018
7 years
 Independent None stated Mineralys Therapeutics, Inc. $383,717
Michael Hayden
73 2018
7 years
 Independent None stated Ionis Pharmaceuticals, Inc. $392,467
Kathleen D. LaPorte
63 2021
4 years
 Independent None stated Cero Therapeutics Holdings, Inc. $398,337
Charles McWherter
70 2024
1 year
 Independent None stated None stated $440,246
Lota Zoth
65 2020
5 years
 Independent None stated Inovio Pharmaceuticals, Inc. $399,967

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

2 disclosed in the proxy filed Apr 15, 2025
Melissa Zaharias
spouse of Quoc Le-Nguyen (our Chief Technical Operations Officer)
Approximately $83,000
January 1, 2024 through March 3, 2024

Quality assurance consulting services provided under a pre-existing arrangement from January 1, 2024 through March 3, 2024.

With the Company Open in proxy
Melissa Zaharias
Approximately $344,000
2024

Employment as Senior Director, Chemistry, Manufacturing and Controls (CMC) Quality Assurance, effective March 4, 2024, with an annualized base salary and target bonus potential, an initial stock option grant of 26,400 shares, and 6,000 restricted stock units granted in December 2024.

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans